Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma

Authors: Koji Inaba, Ryoji Kushima, Naoya Murakami, Yuuki Kuroda, Ken Harada, Mayuka Kitaguchi, Kotaro Yoshio, Shuhei Sekii, Kana Takahashi, Madoka Morota, Hiroshi Mayahara, Yoshinori Ito, Minako Sumi, Takashi Uno, Jun Itami

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

There have been sporadic reports about synchronous as well as metachronous gastric adenocarcinoma and primary gastric lymphoma. Many reports have dealt with metachronous gastric adenocarcinoma in mucosa-associated lymphoid tissue lymphoma of stomach. But to our knowledge, there have been no reports that document the increased incidence of metachronous gastric adenocarcinoma in patients with gastric diffuse large B-cell lymphoma. This retrospective study was conducted to estimate the incidence of metachronous gastric adenocarcinoma after primary gastric lymphoma treatment, especially in diffuse large B-cell lymphoma.

Methods

The retrospective cohort study of 139 primary gastric lymphoma patients treated with radiotherapy at our hospital. Mean observation period was 61.5 months (range: 3.7-124.6 months). Patients profile, characteristics of primary gastric lymphoma and metachronous gastric adenocarcinoma were retrieved from medical records. The risk of metachronous gastric adenocarcinoma was compared with the risk of gastric adenocarcinoma in Japanese population.

Results

There were 10 (7.2%) metachronous gastric adenocarcinoma patients after treatment of primary gastric lymphomas. It was quite high risk compared with the risk of gastric carcinoma in Japanese population of 54.7/100,000. Seven patients of 10 were diffuse large B-cell lymphoma and other 3 patients were mixed type of diffuse large B-cell lymphoma and mucosa associated lymphoid tissue lymphoma. Four patients of 10 metachronous gastric adenocarcinomas were signet-ring cell carcinoma and two patients died of gastric adenocarcinoma. Metachronous gastric adenocarcinoma may have a more malignant potential than sporadic gastric adenocarcinoma. Old age, Helicobacter pylori infection and gastric mucosal change of chronic gastritis and intestinal metaplasia were possible risk factors for metachronous gastric adenocarcinoma.

Conclusion

There was an increased risk of gastric adenocarcinoma after treatment of primary gastric lymphoma, especially of diffuse large B-cell lymphoma.
Appendix
Available only for authorised users
Literature
1.
Kasahara Y, Takemoto M, Morishita A, Kuyama T, Takahashi M, Tanji K: Coexisting adenocarcinoma and malignant lymphoma of the stomach: case report and review of the Japanese literature. Am J Gastroenterol. 1988, 83: 190-193.PubMed
2.
Noda T, Akashi H, Matsueda S, Katsuki N, Shirahashi K, Kojiro M: Collision of malignant lymphoma and multiple early adenocarcinomas of the stomach. Arch Pathol Lab Med. 1989, 113: 419-422.PubMed
3.
Nakamura S, Aoyagi K, Iwanaga S, Yao T, Tsuneyoshi M, Fujishima M: Synchronous and metachronous primary gastric lymphoma and adenocarcinoma: a clinicopathological study of 12 patients. Cancer. 1997, 79: 1077-1085. 10.1002/(SICI)1097-0142(19970315)79:6<1077::AID-CNCR4>3.0.CO;2-D.CrossRefPubMed
4.
Akosa AB, Clark DM, Desa L: Synchronous adenocarcinoma and primary malignant lymphoma of the stomach. Postgrad Med J. 1990, 66: 778-780. 10.1136/pgmj.66.779.778.CrossRefPubMedPubMedCentral
5.
Wotherspoon AC, Isaacson PG: Synchronous adenocarcinoma and low grade B-cell lymphoma of mucosa associated lymphoid tissue (MALT) of the stomach. Histopathology. 1995, 27: 325-331. 10.1111/j.1365-2559.1995.tb01522.x.CrossRefPubMed
6.
Nishino N, Konno H, Baba S, Aoki K, Nishimura T, Arai T, Kino I: Synchronous lymphoma and adenocarcinoma occurring as a collision tumor in the stomach: report of a case. Surg Today. 1996, 26: 508-512. 10.1007/BF00311557.CrossRefPubMed
7.
Hardman WJ, Gal AA, Pascal RR: Gastric adenocarcinoma and low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. South Med J. 1997, 90: 426-430. 10.1097/00007611-199704000-00014.CrossRefPubMed
8.
Ishihama T, Kondo H, Saito D, Yamaguchi H, Shirao K, Yokota T, Hosokawa K, Ono H, Iwabuchi M, Gotoda T, Matsuno Y, Boku N, Ohtsu A, Yoshida S: Clinicopathological studies on coexisting gastric malignant lymphoma and gastric adenocarcinoma: report of four cases and review of the Japanese literature. Jpn J Clin Oncol. 1997, 27: 101-106. 10.1093/jjco/27.2.101.CrossRefPubMed
9.
Kaffes A, Hughes L, Hollinshead J, Katelaris P: Synchronous primary adenocarcinoma, mucosa-associated lymphoid tissue lymphoma and a stromal tumor in a Helicobacter pylori-infected stomach. J Gastroenterol Hepatol. 2002, 17: 1033-1036. 10.1046/j.1440-1746.2002.02649.x.CrossRefPubMed
10.
Sakai T, Ogura Y, Narita J, Suto T, Kimura D, Ainai S, Fujita H, Kamada M: Simultaneous early adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach associated with Helicobacter pylori infection. Gastric Cancer. 2003, 6: 191-196. 10.1007/s10120-003-0241-8.CrossRefPubMed
11.
Suenaga M, Ohta K, Toguchi M, Sato T, Ohyama S, Yamaguchi T, Muto T, Yanagisawa A, Kato Y: Colliding gastric and intestinal phenotype well-differentiated adenocarcinoma of the stomach developing in an area of MALT-type lymphoma. Gastric Cancer. 2003, 6: 270-276. 10.1007/s10120-003-0260-5.CrossRefPubMed
12.
Sellin J, Levin B, Reckard C, Riddell R: Gastric adenocarcinoma following gastric lymphoma. Role of partial gastrectomy. Cancer. 1980, 45: 996-1000. 10.1002/1097-0142(19800301)45:5<996::AID-CNCR2820450527>3.0.CO;2-W.CrossRefPubMed
13.
Brumback RA, Gerber JE, Hicks DG, Strauchen JA: Adenocarcinoma of the stomach following irradiation and chemotherapy for lymphoma in young patients. Cancer. 1984, 54: 994-998. 10.1002/1097-0142(19840915)54:6<994::AID-CNCR2820540609>3.0.CO;2-F.CrossRefPubMed
14.
Zorlu AF, Atahan IL, Gedikoglu G, Ruacan S, Sayek I, Tekuzman G: Does gastric adenocarcinoma develop after the treatment of gastric lymphoma?. J Surg Oncol. 1993, 54: 126-131. 10.1002/jso.2930540214.CrossRefPubMed
15.
Zauber NP, Berman EL: Synchronous and metachronous primary gastric lymphoma and adenocarcinoma: a clinicopathologic study of 12 patients. Cancer. 1998, 82: 226-227. 10.1002/(SICI)1097-0142(19980101)82:1<226::AID-CNCR28>3.0.CO;2-3.CrossRefPubMed
16.
Capelle LG, de Vries AC, Looman CWN, Casparie MK, Boot H, Meijer GA, Kuipers EJ: Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008, 44: 2470-2476. 10.1016/j.ejca.2008.07.005.CrossRefPubMed
17.
18.
Ruskone-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, Montalban C, Raderer M, Savio A, Wotherspoon A: EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011, 60: 747-758. 10.1136/gut.2010.224949.CrossRefPubMed
19.
Hamaloglu E, Topaloglu S, Ozdemir A, Ozenc A: Synchronous and metachronous occurrence of gastric adenocarcinoma and gastric lymphoma: a review of the literature. World J Gastroenterol. 2006, 12: 3564-3574.CrossRefPubMedPubMedCentral
20.
Kellum JM, Jaffe BM, Calhoun TR, Ballinger WF: Gastric complications after radiotherapy for Hodgkin’s disease and other lymphomas. Am J Surg. 1977, 134: 314-317. 10.1016/0002-9610(77)90395-6.CrossRefPubMed
21.
Brown WM, Doll R: Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J. 1965, 2: 1327-1332. 10.1136/bmj.2.5474.1327.CrossRefPubMedPubMedCentral
22.
Abe S, Oda I, Kinjyou Y, Suzuki H, Nonaka S, Yoshinaga S, Makazu M, Sou E, Yachida T, Yamada M, Nakamura Y, Taniguchi H, Sekine S, Kushima R: Case report of early gastric cancer which can be diagnosed easily after Helicobacter Pylori eradication (written in Japanese). Stomach and intestine. 2012, 47: 1695-1699.
23.
Kato M, Ono S, Takahashi M, Shinada K, Haneda M, Yamamoto K, Yoshida T, Mabe K, Shimizu Y, Asaka M, Mori Y, Nakagawa M, Nakagawa S: Multiple gastric carcinoma after Helicobacter pylori eradication (written in Japanese). Stomach and intestine. 2011, 46: 75-82.
24.
Haruma K, Suzuki T, Tsuda T, Yoshihara M, Sumii K, Kajiyama G: Evaluation of tumor growth rate in patients with early gastric carcinoma of the elevated type. Gastrointest Radiol. 1991, 16: 289-292. 10.1007/BF01887370.CrossRefPubMed
Metadata
Title
Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma
Authors
Koji Inaba
Ryoji Kushima
Naoya Murakami
Yuuki Kuroda
Ken Harada
Mayuka Kitaguchi
Kotaro Yoshio
Shuhei Sekii
Kana Takahashi
Madoka Morota
Hiroshi Mayahara
Yoshinori Ito
Minako Sumi
Takashi Uno
Jun Itami
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-499

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer

Research article

CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion

Research article

Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis

Research article

The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin

Research article

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRASexon 2 wild-type metastatic colorectal cancer

Research article

Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits